目的探讨依那普利联合叶酸片在H型高血压患者治疗中的应用价值。方法选取2014年12月至2015年6月于解放军第四六三医院诊治的87例H型高血压患者作研究对象,按照随机抽样原则分成观察组(44例)与对照组(43例)。对照组患者单纯服用依那普利片,观察组患者采用依那普利联合叶酸片进行治疗,比较两组患者治疗前后血压、血浆同型半胱氨酸(Hcy)水平、心脑血管事件发生率及临床疗效。结果治疗后12周,观察组患者的舒张压、收缩压以及Hcy水平均明显低于对照组,差异均有统计学意义(均P<0.05);观察组患者心脑血管事件发生率明显低于对照组,差异有统计学意义(P<0.05);观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05)。结论应用依那普利联合叶酸片治疗H型高血压临床疗效显著,可有效降低患者血压与Hcy水平,且心脑血管事件发生率较低。 Objective To investigate the value of enalaprol in combination with folic acid tablets in the treatment of patients with Hypertension. Methods Totally 87 Hypertensive patients diagnosed and treated in the 463 Hospital of People’s Liberation Army from December 2014 to June 2015 were divided into observation group (44 cases) and control group (43 cases) according to random sampling principle. Patients in the control group received enalapril tablets only. Patients in the observation group were treated with enalapril combined with folic acid tablets. Blood pressure, plasma homocysteine ​​(Hcy) levels, and incidence of cardiovascular and cerebrovascular events were compared between the two groups before and after treatment. And clinical efficacy. Results At 12 weeks after treatment, the diastolic blood pressure, systolic blood pressure and Hcy in observation group were significantly lower than those in control group (all P <0.05). The incidence of cardiovascular and cerebrovascular events in observation group was significantly lower than that in control group The difference was statistically significant (P <0.05). The total effective rate of treatment in observation group was significantly higher than that in control group, the difference was statistically significant (P <0.05). Conclusion The clinical efficacy of enalapril combined with folic acid tablets in the treatment of Hypertension is significant, which can effectively reduce the blood pressure and Hcy level of patients and the incidence of cardiovascular and cerebrovascular events is low.